Viewing Study NCT00274495


Ignite Creation Date: 2025-12-24 @ 1:33 PM
Ignite Modification Date: 2026-02-02 @ 1:42 PM
Study NCT ID: NCT00274495
Status: TERMINATED
Last Update Posted: 2007-11-01
First Post: 2006-01-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
Sponsor: Beth Israel Medical Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Hepatitis C Infection View
None Fatty Liver View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Genotype 1 View
None Metabolic syndrome View
None Insulin resistance View